Jaguar Health, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
JAGX Nasdaq 2830 jaguar.health

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Jaguar Health, Inc.

Jaguar Health, Inc. Announces Reverse Stock Split - Sep 15th, 2026 7:00 am
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF) - Sep 10th, 2026 7:00 am
Jaguar Health Launches Neonorm Dog on Amazon, Expanding Animal-Health Product Franchise - Sep 8th, 2026 9:06 am
Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs - Sep 8th, 2026 7:00 am
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) - Sep 4th, 2026 6:30 am
Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs - Aug 26th, 2026 7:00 am
Jaguar Health Inc (JAGX) (Q2 2026) Earnings Call Highlights: Rare Disease Breakthroughs and ... - Aug 19th, 2026 11:02 pm
Jaguar Health Reports Second Quarter 2026 Financials - Aug 19th, 2026 2:00 pm
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates - Aug 18th, 2026 7:00 am
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1 - Aug 5th, 2026 7:00 am
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog - Jul 28th, 2026 7:00 am
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID) - Jul 22nd, 2026 7:00 am
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF) - Jun 30th, 2026 7:00 am
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing - Jun 26th, 2026 6:35 am
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend - Jun 25th, 2026 7:00 am
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - Jun 23rd, 2026 7:00 am
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th - Jun 23rd, 2026 6:35 am
Sector Update: Healthcare Stocks Rise Late Afternoon - Jun 22nd, 2026 1:43 pm
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program - Jun 22nd, 2026 7:00 am
Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health - Jun 18th, 2026 7:01 am